Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21
Benzinga Newsdesk 2 weeks ago
News
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to feature ATNM-400
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA
Preclinical presentation to feature ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer, exploring its potential across molecular subtypes
ATNM-400's HER3-targeted alpha radiotherapy approach offers pan-cancer potential, with development as a monotherapy and in combination with established treatments across multiple solid tumors.
EANM 2026 Presentation Details
Both sessions: Monday, October 19, 2026, 4:45–6:15 p.m. CEST (10:45 a.m.–12:15 p.m. EDT).
Clinical prostate cancer presentation | OP-525
First-in-human Phase 1 study of ATNM-400 in mCRPC
Session 1111: Theranostics Track: Prostate Cancer Therapy II | Hall G1
Preclinical lung cancer presentation | EPS-149
ATNM-400 in KRAS- and ALK-driven NSCLC models
Session 1109: Translational Imaging and Therapy | Hall G2